A randomized, open-label study of the addition of amantadine to PEGASYS [peginterferon alfa-2a] plus ribavirin on sustained virological response in patients with chronic hepatitis C viral infection who are treatment-naive or have experienced a relapse after treatment with interferon plus ribavirin
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2010
At a glance
- Drugs Amantadine; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Planned number of patients changed from 500 to 660 as reported by Roche record.
- 20 Aug 2008 Status change from recruiting to completed according to Roche protocol registry.
- 20 Jun 2006 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History